Drug Abuse Aspects of Hiv/Aids and Other Infections

Applicants Eligible for this Grant

County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education State governments Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification)

Additional Information on Eligibility

Information not provided

Grant Description

The National Institute on Drug Abuse (NIDA) supports research on the natural history, epidemiology, etiology, virology and pathogenesis, prevention, and treatment of drug abuse and drug abuse aspects of HIV/AIDS and other infectious agents [e.g., hepatitis B virus (HBV), hepatitis C virus (HCV), other sexually transmitted infections (STIs), and tuberculosis (TB)]. AIDS was first recognized as a growing epidemic among men who have sex with men (MSM) and injection drug users (IDUs) and their sexual partners in the early 1980s. While considerable scientific progress has been made since then in understanding, preventing, and treating the intertwined epidemics of drug abuse and HIV/AIDS, much remains unknown or poorly understood today. Emerging drugs of abuse, such as the club drugs ecstasy (MDMA), GHB, ketamine, and methamphetamine, as well as more potent supplies of heroin, cocaine, and marijuana, are continually changing the profiles of populations at risk. Moreover, these drugs often contain adulterants, and are used in risky social contexts in combination with alcohol and other drugs, including Viagra, poppers, and tobacco. In the United States today, over 77,000 women have been diagnosed with AIDS attributed to injection drug use or sex with an IDU, and nearly a third of AIDS cases in adult/adolescent women diagnosed in 2001 reported injection drug use or sex with an IDU as their primary risks. Racial and ethnic minority populations of both genders have been deeply affected by drug abuse, HIV/AIDS, and other infectious diseases in recent years, with new HIV infections continuing at an alarming rate in the U.S. and in other nations. There are an estimated 800,000 to 900,000 people living with HIV in the U.S., with approximately 40,000 new HIV infections occurring every year. By race, more than half of new HIV infections in 2001 and deaths attributable to AIDS in 2000 occurred among African Americans, although they represent only 13% of the U.S. population. This PA seeks to stimulate a range of investigator-initiated studies to advance the scientific knowledge base on drug abuse aspects of HIV/AIDS and other serious infections. Researchers are invited to address diverse and cross-cutting issues in multiple disciplines, including, among others: virology, bacteriology, molecular epidemiology, etiology, therapeutics and vaccines, ethnography and behavioral epidemiology, mathematical modeling and simulations, and the behavioral and social sciences.

Link to Full Grant Announcement

http://grants.nih.gov/grants/guide/pa-files/PA-04-007.html http://grants.nih.gov/grants/guide/pa-files/PA-04-007.html

Grant Announcement Contact

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster FBOWebmaster@OD.NIH.GOV NIH OER Webmaster

Similar Government Grants

• Drug Abuse Dissertation Research (R36)

• NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K...

• Advancing Exceptional Research on HIV/AIDS (R01)

• Research on Marijuana Legalization in the US (Admin Supp)

• Mechanisms, Models, Measurement, & Management in Pain Research (R03)

• NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards

• Epidemiology of Drug Abuse

• Prescription Drug Abuse

More Grants from the National Institutes of Health

• NIAMS Clinical Trial Outcome Instrument Development Grant Program (U01)

• Biophysical and Biomechanical Aspects of Embryonic Development (R01)

• Biophysical and Biomechanical Aspects of Embryonic Development (R21)

• Dual Purpose with Dual Benefit: Research in Biomedicine and Agriculture Using Agricultural...

• MARC Undergraduate Student Training in Academic Research (U-STAR) National Research Servic...